<DOC>
	<DOCNO>NCT00307554</DOCNO>
	<brief_summary>Evaluate lot-to-lot consistency , safety reactogenicity 3 dos GSK Biologicals ' 10-valent pneumococcal conjugate vaccine non-inferiority respect Prevenar .</brief_summary>
	<brief_title>A Lot-to-lot Consistency ( 3 Lots GSK Biologicals ' 10-valent Pneumococcal Conjugate Vaccine ) &amp; Non-inferiority Study</brief_title>
	<detailed_description>Test group : 4 ( 400 subjects/group ) . 3 group receive 10-valent pneumococcal conjugate vaccine ( 3 different lot ) follow : - 10-valent vaccine ( lot 1 , 2 3 ) + DTPa combine vaccine ; Control group receive Prevenar + DTPa combine vaccine</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Male female , include , 6 12 week ( 4290 day ) age time first vaccination , free obvious health problem write informed consent obtain parent/guardian subject . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine within 30 day preceeding first dose study vaccine , plan use study period . Planned administration/ administration license vaccine foreseen study protocol period start one month first dose vaccine ( ) entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>